Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
详细信息 查看全文
- 作者：Thomas K. Eigentlera ; 1 ; thomas.eigentler@med.uni-tuebingen.de" class="auth_mail" title="E-mail the corresponding author ; Jessica C. Hasselb ; 1 ; jessica.hassel@med.uni-heidelberg.de" class="auth_mail" title="E-mail the corresponding author ; Carola Berkingc ; carola.berking@med.uni-muenchen.de" class="auth_mail" title="E-mail the corresponding author ; Jens Aberled ; aberle@uke.de" class="auth_mail" title="E-mail the corresponding author ; Oliver Bachmanne ; bachmann.oliver@mh-hannover.de" class="auth_mail" title="E-mail the corresponding author ; Viktor Grü ; nwaldf ; Gruenwald.Victor@mh-hannover.de" class="auth_mail" title="E-mail the corresponding author ; Katharina C. Kä ; hlerg ; kckaehler@dermatology.uni-kiel.de" class="auth_mail" title="E-mail the corresponding author ; Carmen Loquaih ; Carmen.Loquai@unimedizin-mainz.de" class="auth_mail" title="E-mail the corresponding author ; Niels Reinmuthi ; n.reinmuth@lungenclinic.de" class="auth_mail" title="E-mail the corresponding author ; Martin Steinsj ; martin.steins@med.uni-heidelberg.de" class="auth_mail" title="E-mail the corresponding author ; Lisa Zimmerk ; lisa.zimmer@uk-essen.de" class="auth_mail" title="E-mail the corresponding author ; Anna Sendll ; anna.sendl@bms.com" class="auth_mail" title="E-mail the corresponding author ; Ralf Gutzmerm ; gutzmer.ralf@mh-hannover.de" class="auth_mail" title="E-mail the corresponding author
- 关键词：Immunotherapy ; PD-1 ; Nivolumab ; Pembrolizumab ; Adverse drug reaction ; Immune-related adverse events
- 刊名：Cancer Treatment Reviews
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：45
- 期：Complete
- 页码：7-18
- 全文大小：669 K
文摘
- class="listitem" id="list_l0005">
- class="label">•
Immune-mediated adverse drug reactions of grade 3–4 occur in up to 2% in the standard organ classes (according to MedDRA).
- class="label">•
Early diagnosis and treatment is a key to manage immune-mediated adverse events.
- class="label">•
Most immune-related adverse events are clinically well-manageable by use of systemic corticosteroids.
- class="label">•
Anti-PD-1 therapy restart is indicated after recovery of events of mild or moderate severity.